Archives
Author Archive for: "Joost_content_2019"
Author Archive for: "Joost_content_2019"
This author has not yet written his bio.Meanwhile let's just say that we are proud Joost Bakker contributed with 50 entries.
– Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested in HIV-positive male patients
Leiden, The Netherlands, September 16, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia (AIN). The study is supported by ZonMw, the Dutch Organisation for Health Research and Development, and is being conducted in The Netherlands.
ISA101 is a synthetic long peptide (SLP®) vaccine for the treatment of diseases induced
Read more »– Study published in European Journal of Immunology elucidates different, improved antigen presentation and T cell-inducing power of SLP® vaccines
Leiden, The Netherlands, September 4, 2013 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced the publication of a peer-reviewed paper in the European Journal of Immunology.[1] The article describes a previously unknown mechanism that explains the excellent efficacy of ISA’s Synthetic Long Peptide (SLP®) vaccines. The authors demonstrate that compared to whole protein antigens, SLP®s are processed much more rapidly and efficiently by dendritic cells (DCs),
Read more »– Local Delivery of Checkpoint Control Antibodies Greatly Improve Efficacy and Safety
– Promising Potential for Combinatorial Strategies
Leiden, The Netherlands, July 15, 2013 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced the publication of three peer-reviewed papers that demonstrate the benefit of local delivery of a checkpoint control antibody targeting CTLA-4 (cytotoxic T lymphocyte antigen-4) for the successful eradication of cancer and the reduction of side effects. The papers include a review that underlines the importance of strategies for combinatorial treatments to improve further the immunotherapy
Read more »– Company hires Jan Fagerberg as Chief Medical Officer and Jens Hennecke as Chief Business Officer
– Ronald Loggers becomes Acting Chief Executive Officer and Gerard Platenburg Chief Operating Officer
Leiden, The Netherlands, July 08, 2013 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that it has appointed Dr. Jan Fagerberg, M.D., Ph.D., as Chief Medical Officer and Dr. Jens Hennecke, Ph.D., as Chief Business Officer and Advisor. Furthermore, Ronald Loggers, M.Sc., MBA, will step down from the Board of Directors and assume the role of Acting Chief
Read more »– AMPLIVANT™ TLR-ligand adjuvant to improve immunotherapies –
Leiden, The Netherlands, April 9, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, announces that Cornelis Melief, Professor at Leiden University and Chief Scientific Officer of ISA, presented details on the company’s novel AMPLIVANT™ technology at the American Association for Cancer Research (AACR) 2013 Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand designed to improve immunotherapies. This promotes direct dendritic cell targeting of the antigen as well as antigen processing, resulting in long-term activation of
Read more »Leiden, The Netherlands, April 2, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT™ platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.
Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“
Symposium: SY27 “New Cancer Vaccines“
Abstract number: SY27-01
Date: April 9, 2013, at 10:40 a.m.
Location: Room 202 at the Washington Convention Center.
The abstract is available at the AACR
Read more »Leiden, the Netherlands, January 7, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has today announced that it has raised EUR 8 million in a follow-on round from its existing investor base.
The proceeds will be used to fund a randomized Phase II clinical trial in cervical cancer with ISA’s lead program ISA-HPV, a therapeutic vaccine for pre-malignant diseases and cancers induced by human papilloma virus (HPV). Cervical cancer is the second most common cancer in women worldwide and is caused by HPV infection. The company has already
Read more »Leiden, The Netherlands, October 17th, 2011 – ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van de Winkel has joined its Supervisory Board.
“We are excited to have Jan van de Winkel strengthening our Supervisory Board. He complements an experienced and motivated team, the collective experience of which spans the biotechnological, pharmaceutical and financial areas. We expect ISA to benefit from his insights and expertise and look forward to interacting with Jan to further propel the company in the rapidly emerging field of immunotherapy.” says Gerard Platenburg, managing
Read more »Leiden, The Netherlands, October 5th , 2011 – ISA Pharmaceuticals BV, a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that orphan drug designation has been granted to its lead compound for the treatment of vulvar intraepithelial neoplasia (VIN) by the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA). Orphan drug designation is granted by the FDA to promote the development of products that may offer therapeutic benefits for diseases affecting less than 200,000 people in the USA. Orphan drug designations are based on several criteria that include
Read more »ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Transgene (Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced the signing of an exclusive license agreement. Transgene will use ISA’s proprietary IP in Transgene’s program for developing novel vaccines to combat infectious diseases caused by mycobateria tuberculosis, such as TB. Under the terms of the agreement, ISA will receive an upfront fee and could receive payments on the achievement by Transgene of research and clinical milestones, as well as royalties on
Read more »